Conscience May 2026 Policy Brief - Federal Action to Accelerate Psychedelic Treatments for Serious Mental Illness
Zenodo (CERN European Organization for Nuclear Research) May 26, 2026 DOI: 10.5281/zenodo.20402457 via OpenAlex
Summary
AI-generated from the abstractPresident Trump signed an executive order on April 18, 2026, titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to speed up the development and availability of psychedelic treatments for serious mental health conditions. The order marks a major federal policy shift, as psychedelic research has been historically limited by Schedule I controlled substance restrictions. It introduces priority review vouchers and outlines lessons learned from past regulatory barriers.
Study at a glance
| Characteristics | Peer reviewed |
|---|---|
| Keywords | Mental illness Pace Action physics Mental health Executive order |
| Key finding | The executive order aims to accelerate psychedelic treatments for serious mental illness by granting priority review vouchers and addressing regulatory barriers. |
Abstract
Federal Action to Accelerate Psychedelic Treatments for Serious Mental Illness President Trump signed an executive order (the “Order”), on April 18th 2026, titled “Accelerating Medical Treatments for Serious Mental Illness”. The Order addresses the slow pace of development and limited availability of psychedelic treatments for serious mental health conditions. This represents a major shift in federal policy as psychedelic drug research has historically been limited by regulatory barriers, especially restrictions connected to Schedule I controlled substances. This policy introduces the purpose of the executive order, the granting of priority review vouchers, and potential lessions learned.